- Joined
- Sep 22, 2008
- Messages
- 84,659
- Points
- 113
Guess wot? Excess deaths continues despite covid vaccine in the west.
- Thread starter syed putra
- Start date
- Joined
- Sep 22, 2008
- Messages
- 84,659
- Points
- 113
15% excess deaths in Netherlands. 9% in Denmark.
- Joined
- Sep 14, 2014
- Messages
- 6,859
- Points
- 113
It's engineer to kill those white ppl ,evil bit it failed as asian also hv many deaths or sick,fuck tiong
- Joined
- May 16, 2023
- Messages
- 40,489
- Points
- 113
No wallory...Pfizer has the gene therapy treatment portfolio for mass public by 2030
Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
PUBLISHED SUN, MAR 10 2024 8:00 AM EDT
Annika Kim Constantino
@ANNIKAKIMC
Pfizer is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business.
The pharmaceutical giant has been trying to shore up investor sentiment after its shares fell more than 40% in 2023.
Pfizer says its combined drug pipeline with cancer drugmaker Seagen could produce at least eight blockbuster medicines by 2030.
https://www.google.com/amp/s/www.cn...-big-on-cancer-drugs-after-covid-decline.html
- Joined
- May 16, 2023
- Messages
- 40,489
- Points
- 113
Boshoff highlighted the scale of Pfizer's capabilities, noting it has 10 manufacturing sites producing cancer drugs on three continents, while Seagen had just one. He also pointed to Pfizer's commercial presence in more than 100 countries and a customer-facing commercial team that is triple the size of Seagen's.
Pfizer did not provide a specific sales projection for its oncology franchise by 2030. But the company said it expects roughly two-thirds of risk-adjusted oncology revenue to come from new drugs and new indications — or treatment uses — for existing products by the end of the decade.
Pfizer did not provide a specific sales projection for its oncology franchise by 2030. But the company said it expects roughly two-thirds of risk-adjusted oncology revenue to come from new drugs and new indications — or treatment uses — for existing products by the end of the decade.
- Joined
- May 16, 2023
- Messages
- 40,489
- Points
- 113
A new focus
Pfizer also highlighted a huge shift in its drug pipeline strategy.
Boshoff said the oncology division plans to shift to biologic drugs as its main source of revenue, increasing the proportion of those treatments in its pipeline from 6% to 65% by 2030.
Biologics are treatments derived from living sources such as animals or humans, including vaccines, stem cell treatments and gene therapies. They are among the most expensive prescription drugs in the U.S.
Before the Seagen deal, 94% of Pfizer's cancer products were small-molecule drugs. Those medicines are made of chemicals and have low molecular weights.
Pfizer also highlighted a huge shift in its drug pipeline strategy.
Boshoff said the oncology division plans to shift to biologic drugs as its main source of revenue, increasing the proportion of those treatments in its pipeline from 6% to 65% by 2030.
Biologics are treatments derived from living sources such as animals or humans, including vaccines, stem cell treatments and gene therapies. They are among the most expensive prescription drugs in the U.S.
Before the Seagen deal, 94% of Pfizer's cancer products were small-molecule drugs. Those medicines are made of chemicals and have low molecular weights.
- Joined
- May 16, 2023
- Messages
- 40,489
- Points
- 113
Four core cancer types
Pfizer plans to focus on four main types of cancer: breast cancer; genitourinary cancer, which impacts urinary and genital organs or functions; thoracic cancer, such as lung, head and neck cancer; and hematology-oncology, or cancers of the blood, such as multiple myeloma and lymphomas.
Pfizer expects breast cancer's contribution to total oncology sales to drop to about 10% by 2030 from roughly 40% last year, the company's oncology commercial chief Suneet Varma said during the event.
That decline accounts for the upcoming loss of exclusivity of top-seller Ibrance, which raked in $4.75 billion in sales in 2023.
But the company said it has a handful of breast cancer drugs in development that could become "potential growth drivers" as Ibrance sales fall. That includes a certain type of treatment called atirmociclib that could potentially be more effective and easier for patients to tolerate.
Pfizer is testing the medicine as a second-line treatment for a certain type of breast cancer in a phase three trial. A second-line therapy is given when an initial treatment doesn't work or stops working.
The company also plans to start a separate late-stage trial on atirmociclib as a first treatment for the same condition in the second half of the year.
Pfizer plans to focus on four main types of cancer: breast cancer; genitourinary cancer, which impacts urinary and genital organs or functions; thoracic cancer, such as lung, head and neck cancer; and hematology-oncology, or cancers of the blood, such as multiple myeloma and lymphomas.
Pfizer expects breast cancer's contribution to total oncology sales to drop to about 10% by 2030 from roughly 40% last year, the company's oncology commercial chief Suneet Varma said during the event.
That decline accounts for the upcoming loss of exclusivity of top-seller Ibrance, which raked in $4.75 billion in sales in 2023.
But the company said it has a handful of breast cancer drugs in development that could become "potential growth drivers" as Ibrance sales fall. That includes a certain type of treatment called atirmociclib that could potentially be more effective and easier for patients to tolerate.
Pfizer is testing the medicine as a second-line treatment for a certain type of breast cancer in a phase three trial. A second-line therapy is given when an initial treatment doesn't work or stops working.
The company also plans to start a separate late-stage trial on atirmociclib as a first treatment for the same condition in the second half of the year.
Similar threads
